Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Those rules are only for the big boards and I think it only related to price drops. We can go from .06 to $1 in one day and nothing can stop us :)
I haven't seen any newsletters or anything. Company released some good news and an updated presentation so maybe that's what's up. If it was being pumped it would be much more volume in the millions.
great volume today and nice steady rise. IMO this is just the beginning - .08 just got hit!
2017 Anaheim State of the City
.06's getting hit....
The updated investor presentation is in the 8K -
https://www.otcmarkets.com/edgar/GetFilingPdf?FilingID=11831338
the new version should be available on the website soon.
I am looking forward to news of a closed deal with a real company. If VALIDIAN has the good then it should be no problem closing a deal.
There are other companies that sell the implant so it's not exclusive.
I don't think he needs to report anymore since he is not part of the company so it is def out of date.
0 volume and big offers stacked up. This doesn't smell good...
Welcome Kizersosae-
The company is still pushing the implant, but the main focus is getting the new improved form of injectable Neltrexone FDA approved. check out my post#7657 and you will find a link to the investor presentation.
The company is 100% legit and I have spoken to the CEO and met a few employees when I visited the office in Californa a couple years ago. If you take a look at the filings you will see none of the company management has sold any shares or exercised stock options. There is one individual who was part of the company early on and had 10mm shares who IMO is responsible for the selling. He is no longer involved with the company and IMO should only have a couple million shares left at this point. good luck
nice article mentioning BICX and ALKS..
Naltrexone Showing More Potential in Drug Addiction Treatment Market
In the on-going debate of which drug addiction treatment is more effective, naltrexone is showing more potential than buprenorphine, according to the latest study by researchers from Columbia University.
The results of the study will have a profound impact on the $35 billion drug addiction treatment market as this could influence which treatment method gets the bigger slice of the pie.
Maria Sullivan of College of Physicians and Surgeons of Columbia University and lead researcher of the study, said that an outpatient detoxication regimen using naltrexone was more effective for transitioning adults with opioid dependence to extended-release naltrexone than a regimen using buprenorphine.
"An extended-release injectable form of naltrexone has FDA approval for relapse prevention following opioid detoxification," Sullivan said. "However, a substantial barrier to its effective implementation is the need to detoxify patients from opioids before naltrexone is initiated."
About Naltrexone
Naltrexone is a popular medication used to block the effects of opioids. The oral form is sold under the brand name Revia, which is manufactured by Barr Laboratories, a subsidiary of Teva Pharmaceuticals (TEVA), an Israeli-based pharmaceutical giant with $19.7 billion in revenues in 2015. A once-monthly extended-release injectable formulation is marketed under the trade name Vivitrol, which is manufactured by Alkermes PLC (ALKS), an $8 billion pharmaceutical company.
Brady Granier, president and CEO of BioCorRx Inc. (BICX), a California company developing sustained release naltrexone products under its subsidiary BioCorRx Pharmaceuticals, stated "naltrexone has multiple uses and is an old, but fascinating medication. It's effective for both alcoholism and opioid addiction and is worthy of becoming the gold standard for relapse prevention."
Naltrexone with initial dose of Buprenorphine can increase patient acceptability
The researchers at Columbia University said in their report, "The study results support the feasibility of ascending low doses of oral naltrexone, in combination with an initial dose of buprenorphine and standing nonopioid ancillary medications, as an outpatient regimen for opioid detoxification and [extended-release naltrexone] induction. By circumventing the need for a protracted period of abstinence and mitigating the severity of withdrawal symptoms experienced during detoxification, this strategy has the potential to considerably increase patient acceptability of, and access to, antagonist therapy."
The researchers conducted the study amongst 150 individuals with opioid dependence who were selected randomly to assess the efficacy of an approach for transitioning adults with opioid dependence to extended-release injection naltrexone while preventing relapse. The participants were assigned to receive naltrexone-assisted detoxification or buprenorphine-assisted detoxification, followed by an injection of extended-release naltrexone.
Naltrexone-assisted detoxification included one day of buprenorphine followed by increasing doses of oral naltrexone, clonidine and other adjunctive medications for seven days. Buprenorphine-assisted detoxification included a seven-day buprenorphine taper followed by a seven-day delay before administration of extended-release naltrexone.
Participants who received naltrexone-assisted detoxification were significantly more likely to receive extended-release naltrexone (56.1% versus 32.7%) and receive a second injection at week five (50% versus 26.9%), compared with the buprenorphine-assisted group.
These findings remained consistent when adjusting for primary type of opioid use, route of opioid administration and morphine equivalents at baseline.
Patients treated with Buprenorphine more likely to disengage from treatment
A separate study published in the Journal of Substance Abuse Treatment showed that black or Hispanic patients with opioid dependency who are treated with buprenorphine are more likely to discontinue the treatment program. The same observation was made amongst patients with opioid dependency who have hepatitis C.
Another study was conducted by the Boston University School of Medicine and the School of Public Health by examining patients treated at the Boston Medical Center's Office Based Addiction Treatment program between 2002 and 2014 to better understand why certain groups disengage from buprenorphine treatment.
Researchers have found that many individuals who participate in OBAT with buprenorphine discontinue treatment less than one year after the initiation. It added that older patients, females and co-morbid psychiatric diagnosed patients show higher treatment retention after one year, but black, Hispanic, unemployed and those with hepatitis C have decreased chances of retaining treatment after one year.
Brady added "I'm encouraged by the advances in detoxification products and protocols. There are many new treatments on the horizon that should allow for a more efficient and tolerable transition from opioids to sustained released naltrexone products by those suffering."
Currently, BioCorRx is in the early stage of developing a new injectable naltrexone product called BICX101 under its subsidiary BioCorRx Pharmaceuticals. BioCorRx said that it plans to offer BICX101 at a lower price than the leading Vivitrol brand and expects BICX101 to be less painful when administered due to an anticipated smaller needle size and less injection volume.
Disclosure: I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours. I have no business relationship with any company whose stock is mentioned in this article.
http://finance.yahoo.com/news/naltrexone-showing-more-potential-drug-232117997.html
seems like it was just based on technicals...
Funny how everyone is still asking the big money questions.
That's gonna be in the next PR for version 3.2 - lol
What's going on in July? You keep mentioning that month.
"That leaves only one question, ARE THE CLAIMS MADE BY BRUCE BENN AND VALIDIAN CORPORATION ABOUT the ValidianProtect TECHNOLOGY TRUE?"
Can you share another employee we can contact at the company to speak to?
Read the TOS lol
Glad I unloaded some shares in the .05's. Hopefully it goes back there again soon.
IMO - we have an FDA status update coming any day now. That might explain the buying the past couple of weeks.
Connect the dots baby! The PR is an advanced cyber security algorithm. It's the future and no one has it except first to market
Almost 600K in offers around .035ish - wait, those must be fake.. Maybe the shorts put them there...
ya, I bet they are all beating down the door to their hands on the product. Wait, I forgot, there is no door or office for that matter.
only took the first few sentences to realized it was a useless PR AGAIN.
What do you think is the next catalyst for a move? Seems like this company is getting more and more press.
Glad I didn't buy options. I never bank on the timing these biotech companies give you. The management and transparency of this company is great so all we need is the drug to work.
Did Linda and gang get their dose of tamiflu? I hope everyone is better and the update on P3 is being prepared. :)
What are you looking for? Revenue booked with ganthet? Meaningless in my book. I am want to see a deal with a real company.
So what would 20 billion market cap be in PPS?
2 years? Lol - you mean 12 years.
Maybe another run to .30 coming? Hmmmm
S&P and DOW are up big the past 2 years, but 0% return on my money is good huh?
I am sure you will get a 20 paragraph reply with a lot of "what ifs" "connect the dots" "walk the narrow line of communicating" "NDAs" "secrets" blah blah blah - NO FACTS
all garbage - figures
I hope your kidding about that radio interview and SNN - lol. I would take it seriously if it was Fox or Bloomberg.
Sorry Preacher, Validian has had many years to get things going. It is time to deliver with no more excuses - I have put away my decoder ring.
I guess we are all going to have to bust out our Cracker Jack Box Decoder Rings to decrypt the PRs - lol.
A press release, news release, media release, press statement or video release is a written or recorded communication directed at members of the news media for the purpose of announcing something ostensibly newsworthy. (https://en.wikipedia.org/wiki/Press_release)
VLDI to $30! I heard Bruce has a meeting with Trump to discuss the cyber security industry!
Nice volume and price movement today. Almost seems like someone knows something and is buying.
"Talks with majors" could mean cold calling. That's why the PRs are so vague with little or no information.
People are slowly accumulating trying not to raise the price much.